192 related articles for article (PubMed ID: 25521397)
1. Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.
Malik SM; Pazdur R; Abrams JS; Socinski MA; Sause WT; Harpole DH; Welch JJ; Korn EL; Ullmann CD; Hirsch FR
J Thorac Oncol; 2014 Oct; 9(10):1443-8. PubMed ID: 25521397
[TBL] [Abstract][Full Text] [Related]
2. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
3. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
Tsao AS; Lindwasser OW; Adjei AA; Adusumilli PS; Beyers ML; Blumenthal GM; Bueno R; Burt BM; Carbone M; Dahlberg SE; de Perrot M; Fennell DA; Friedberg J; Gill RR; Gomez DR; Harpole DH; Hassan R; Hesdorffer M; Hirsch FR; Hmeljak J; Kindler HL; Korn EL; Liu G; Mansfield AS; Nowak AK; Pass HI; Peikert T; Rimner A; Robinson BWS; Rosenzweig KE; Rusch VW; Salgia R; Sepesi B; Simone CB; Sridhara R; Szlosarek P; Taioli E; Tsao MS; Yang H; Zauderer MG; Malik SM
J Thorac Oncol; 2018 Nov; 13(11):1655-1667. PubMed ID: 30266660
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer.
Falconi A; Lopes G; Parker JL
J Thorac Oncol; 2014 Feb; 9(2):163-9. PubMed ID: 24419412
[TBL] [Abstract][Full Text] [Related]
5. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
LoRusso PM; Boerner SA; Seymour L
Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
[TBL] [Abstract][Full Text] [Related]
6. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.
Khleif SN; Doroshow JH; Hait WN;
Clin Cancer Res; 2010 Jul; 16(13):3299-318. PubMed ID: 20501613
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
[TBL] [Abstract][Full Text] [Related]
8. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
9. Master protocols in lung cancer: experience from Lung Master Protocol.
Lam VK; Papadimitrakopoulou V
Curr Opin Oncol; 2018 Mar; 30(2):92-97. PubMed ID: 29329112
[TBL] [Abstract][Full Text] [Related]
10. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
12. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
Do K; O'Sullivan Coyne G; Chen AP
Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
[TBL] [Abstract][Full Text] [Related]
13. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.
Tahara H; Sato M; Thurin M; Wang E; Butterfield LH; Disis ML; Fox BA; Lee PP; Khleif SN; Wigginton JM; Ambs S; Akutsu Y; Chaussabel D; Doki Y; Eremin O; Fridman WH; Hirohashi Y; Imai K; Jacobson J; Jinushi M; Kanamoto A; Kashani-Sabet M; Kato K; Kawakami Y; Kirkwood JM; Kleen TO; Lehmann PV; Liotta L; Lotze MT; Maio M; Malyguine A; Masucci G; Matsubara H; Mayrand-Chung S; Nakamura K; Nishikawa H; Palucka AK; Petricoin EF; Pos Z; Ribas A; Rivoltini L; Sato N; Shiku H; Slingluff CL; Streicher H; Stroncek DF; Takeuchi H; Toyota M; Wada H; Wu X; Wulfkuhle J; Yaguchi T; Zeskind B; Zhao Y; Zocca MB; Marincola FM
J Transl Med; 2009 Jun; 7():45. PubMed ID: 19534815
[TBL] [Abstract][Full Text] [Related]
14. A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.
Hall JA; Salgado R; Lively T; Sweep F; Schuh A
Lancet Oncol; 2014 Apr; 15(4):e184-93. PubMed ID: 24694642
[TBL] [Abstract][Full Text] [Related]
15. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research.
Punturieri A; Szabo E; Croxton TL; Shapiro SD; Dubinett SM
J Natl Cancer Inst; 2009 Apr; 101(8):554-9. PubMed ID: 19351920
[TBL] [Abstract][Full Text] [Related]
16. Regulatory Forum commentary: through the looking glass--SENDing the pathology data we have INHAND.
Keenan CM; Goodman DG
Toxicol Pathol; 2014 Jul; 42(5):807-10. PubMed ID: 23599411
[TBL] [Abstract][Full Text] [Related]
17. Imaging as a tumor biomarker in oncology drug trials for lung cancer: the FDA perspective.
Petrick N; Brown DG; Suleiman O; Myers KJ
Clin Pharmacol Ther; 2008 Oct; 84(4):523-5. PubMed ID: 18716616
[TBL] [Abstract][Full Text] [Related]
18. Development of an NIH consortium for preclinicAl AssESsment of CARdioprotective therapies (CAESAR): a paradigm shift in studies of infarct size limitation.
Lefer DJ; Bolli R
J Cardiovasc Pharmacol Ther; 2011; 16(3-4):332-9. PubMed ID: 21821536
[TBL] [Abstract][Full Text] [Related]
19. Review of ongoing clinical trials in non-small-cell lung cancer: a status report for 2012 from the ClinicalTrials.gov Web site.
Subramanian J; Regenbogen T; Nagaraj G; Lane A; Devarakonda S; Zhou G; Govindan R
J Thorac Oncol; 2013 Jul; 8(7):860-5. PubMed ID: 23478543
[TBL] [Abstract][Full Text] [Related]
20. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).
Helfer JL; Wen PY; Blakeley J; Gilbert MR; Armstrong TS
Neuro Oncol; 2016 Mar; 18 Suppl 2(Suppl 2):ii26-ii36. PubMed ID: 26989130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
